JP2012144538A5 - - Google Patents

Download PDF

Info

Publication number
JP2012144538A5
JP2012144538A5 JP2012040759A JP2012040759A JP2012144538A5 JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5 JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
tumor
antagonist
coded
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012040759A
Other languages
English (en)
Japanese (ja)
Other versions
JP5719322B2 (ja
JP2012144538A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012144538A publication Critical patent/JP2012144538A/ja
Publication of JP2012144538A5 publication Critical patent/JP2012144538A5/ja
Application granted granted Critical
Publication of JP5719322B2 publication Critical patent/JP5719322B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012040759A 2004-06-18 2012-02-27 腫瘍の治療 Expired - Lifetime JP5719322B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58074504P 2004-06-18 2004-06-18
US60/580,745 2004-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007516758A Division JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2012144538A JP2012144538A (ja) 2012-08-02
JP2012144538A5 true JP2012144538A5 (https=) 2013-05-09
JP5719322B2 JP5719322B2 (ja) 2015-05-13

Family

ID=35351719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007516758A Expired - Lifetime JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療
JP2012040759A Expired - Lifetime JP5719322B2 (ja) 2004-06-18 2012-02-27 腫瘍の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007516758A Expired - Lifetime JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療

Country Status (7)

Country Link
US (2) US8147827B2 (https=)
EP (1) EP1786466B1 (https=)
JP (2) JP5039544B2 (https=)
AU (1) AU2005265067B2 (https=)
CA (1) CA2570887C (https=)
ES (1) ES2429041T3 (https=)
WO (1) WO2006009805A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998255B1 (en) * 1999-09-24 2006-02-14 Solvay Pharmaceuticals B.V. Human G-protein coupled receptor
WO2007018316A1 (ja) * 2005-08-09 2007-02-15 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
NZ566395A (en) * 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
US20080124329A1 (en) * 2006-07-05 2008-05-29 Schreiner George F Conditioned Cell Immunization
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
JP2011074093A (ja) * 2008-06-02 2011-04-14 Univ Of Tokyo 抗がん剤
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
WO2009147695A1 (ja) * 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
JP4686733B2 (ja) * 2008-06-02 2011-05-25 国立大学法人 東京大学 抗がん剤
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
WO2012118806A2 (en) * 2011-02-28 2012-09-07 The Regents Of The University Of California Compositions and methods for detecting and treating cancer
JP5771123B2 (ja) * 2011-11-09 2015-08-26 株式会社 資生堂 プロフィラグリンｃ末端ドメイン特異的抗体及びその用途
JP2013235003A (ja) * 2012-05-10 2013-11-21 Fujita Gakuen 細胞におけるｄｎａ損傷の検出方法及びｄｎａ鎖切断応答性細胞表面抗原に対する抗体
GB201213652D0 (en) * 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
MX2015014486A (es) * 2013-04-15 2016-07-21 Regeneron Pharma Marcadores de respuesta de células tumorales a la terapia.
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
WO2020106049A1 (ko) * 2018-11-20 2020-05-28 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
WO2000073479A1 (en) * 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
US6652853B2 (en) 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
AU2002328945A1 (en) * 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Methods for improved treatment of cancer with irinotecan based on mrp1
DE602004014485D1 (de) 2003-04-07 2008-07-31 Prospect Therapeutics Inc Zusammensetzung und anwendungen von galectin-antagonisten

Similar Documents

Publication Publication Date Title
JP2012144538A5 (https=)
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
JP2012140442A5 (https=)
JP2015512729A5 (https=)
JP2013546230A5 (https=)
JP2012531046A5 (https=)
BR112014016889A8 (pt) composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
GB201411008D0 (en) Determining social sentiment using physiological data
PL2612551T5 (pl) Kompozycja roztoczy zawierająca roztocza drapieżnego i unieruchomiony żer w kontakcie ze środkiem ograniczającym grzyby oraz sposoby i zastosowania dotyczące stosowania wspomnianej kompozycji
JP2014530840A5 (https=)
SI2900279T1 (sl) GRPR-antagonisti za detekcijo, diagnozo in zdravljenje GRPR-pozitivnega raka
EP2858378A4 (en) ULTRASONIC ECHOLOT CONVERTER AND ULTRASONIC FLOWMETER THEREWITH
Casals et al. Next-generation sequencing approaches for genetic mapping of complex diseases
IL228771A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
WO2013188605A3 (en) Predictive markers for cancer and metabolic syndrome
JP2013140343A5 (https=)
JP2014507563A5 (https=)
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
IL233875A0 (en) A preparation and its use for the treatment of anal fissures
JP2014529579A5 (https=)
CL2014003484A1 (es) Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.
HK1206985A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics
PL3027208T3 (pl) Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych
JP2015508319A5 (https=)
CN301998324S (zh) 笔(552)